About Us Resources Catalysts Start Free Trial →

Loading…

Day Trader Sniper provides algorithmic alerts and analysis, not trade advice.
Not financial advice. Trade at your own risk.

Quick Links

Download The App Resources Market Feed Stocks

Catalysts About Us Support Privacy policy Terms of use

©2026 Day Trader Sniper - all rights reserved

Home›Catalysts›Regulatory and Clinical

Catalyst Category

Regulatory and Clinical

Live feed of every catalyst classified under Regulatory and Clinical.

CATALYSTS IN FEED

168

AVG MAX MOVE

+116.8%

POSITIVE MOVES

100%

LARGEST MOVE

+664.1%

DSMB Efficacy Met FDA 510(k) Cleared FDA Approval FDA Fast Track FDA Meeting FDA Meeting Granted Generic Drug Approved Inconclusive Topline Results IND Cleared for Study IND Filed NDA Resubmission Orphan Drug Designation Positive Subgroup Data Positive Topline Results Primary Endpoint Met SPA Agreement Study Complete Trial Enrollment Complete

Range–

Showing 7 of 168

Regulatory and ClinicalMar 10, 2025 · 9:35am ET

SNOASonoma Pharmaceuticals, Inc. Common Stock

Sonoma Pharmaceuticals Receives U.K. Regulatory Clearances for Wound Care and Dermatology Products

The clearances were granted by the Medicines and Healthcare products Regulatory Agency (MHRA).

Be first on the next Regulatory and Clinical catalyst.

Day Trader Sniper alerts you the instant a setup like this triggers.

Download Free →

Max move

+102.1%

RVOL

4.1x

Max high

$4.75

Fuel

13h 19m

Regulatory and ClinicalMar 10, 2025 · 9:35am ET

SNOASonoma Pharmaceuticals, Inc. Common Stock+102.1%

Sonoma Pharmaceuticals Receives U.K. Regulatory Clearances for Wound Care and Dermatology Products

RVOL

4.1x

Max high

$4.75

Fuel

13h 19m

Regulatory and ClinicalFeb 24, 2025 · 3:57pm ET

ADILAdial Pharmaceuticals, Inc

Adial Pharmaceuticals Receives Positive FDA Feedback on AD04 Bridging Strategy

Company advances development of AD04 with FDA support.

Regulatory and ClinicalFeb 24, 2025 · 3:57pm ET

ADILAdial Pharmaceuticals, Inc+92.0%

Adial Pharmaceuticals Receives Positive FDA Feedback on AD04 Bridging Strategy

Regulatory and ClinicalFeb 18, 2025 · 6:46am ET

SLDBSolid Biosciences Inc.

Solid Biosciences Announces Pricing of Underwritten Offering and Positive Clinical Data

Company to issue common stock and pre-funded warrants

Regulatory and ClinicalFeb 18, 2025 · 6:46am ET

SLDBSolid Biosciences Inc.+109.2%

Solid Biosciences Announces Pricing of Underwritten Offering and Positive Clinical Data

Regulatory and ClinicalFeb 13, 2025 · 5:31pm ET

OSTXOS Therapies Incorporated

OS Therapies Inks Agreements for Commercial Manufacture of Lead Cancer Drug

Initiates commercial-ready manufacturing of OST-HER2.

Regulatory and ClinicalFeb 13, 2025 · 5:31pm ET

OSTXOS Therapies Incorporated+108.0%

OS Therapies Inks Agreements for Commercial Manufacture of Lead Cancer Drug

Regulatory and ClinicalFeb 3, 2025 · 3:59pm ET

QNTMQuantum Biopharma Ltd.

Quantum Biopharma Ltd. Announced Success of unbuzzd™ Clinical Trial

Trial demonstrated significant reduction in alcohol-related symptoms.

Regulatory and ClinicalFeb 3, 2025 · 3:59pm ET

QNTMQuantum Biopharma Ltd.+137.9%

Quantum Biopharma Ltd. Announced Success of unbuzzd™ Clinical Trial

Regulatory and ClinicalJan 29, 2025 · 7:03pm ET

KZIAKazia Therapeutics Limited American Depositary Shares

Kazia Therapeutics Launches Clinical Trial for Paxalisib and Immunotherapy in Advanced Breast Cancer

Regulatory approval granted for the trial.

Regulatory and ClinicalJan 29, 2025 · 7:03pm ET

KZIAKazia Therapeutics Limited American Depositary Shares+75.0%

Kazia Therapeutics Launches Clinical Trial for Paxalisib and Immunotherapy in Advanced Breast Cancer

Regulatory and ClinicalJan 21, 2025 · 7:31am ET

INMInMed Pharmaceuticals Inc. Common Shares

InMed Pharmaceuticals Announces Preclinical Success of INM-901 in Reducing Alzheimer's-Related Inflammation

Company reports statistically significant reductions in key neurodegeneration and neuroinflammatory markers.

Regulatory and ClinicalJan 21, 2025 · 7:31am ET

INMInMed Pharmaceuticals Inc. Common Shares+91.4%

InMed Pharmaceuticals Announces Preclinical Success of INM-901 in Reducing Alzheimer's-Related Inflammation

1
…
21
22
23
24

RVOL

14.5x

Max high

$36.25

Fuel

28m

RVOL

3.7x

Max high

$8.43

Fuel

1h 15m

RVOL

8.0x

Max high

$4.14

Fuel

22m

RVOL

13.9x

Max high

$7.40

Fuel

1h

RVOL

4.8x

Max high

$14.00

Fuel

17m

RVOL

14.3x

Max high

$9.17

Fuel

10m